drugset
drugset / Trial / NCT04502433

Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)

NCT04502433 ↗

Phase 2 Terminated 22 enrolled Chiesi Farmaceutici S.p.A.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study was to evaluate the efficacy and safety of poractant alfa (Curosurf®), administered by endotracheal (ET) instillation in hospitalized adult patients diagnosed with SARS-COV-19 acute respiratory distress syndrome (ARDS).

Timeline

Start
2021-01-06
Primary completion
2022-03-17
Completion
2022-03-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Poractant alfa Other / unclassified 30 mg/kg Other

Indications

adult acute respiratory distress syndrome